Overview

SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis

Status:
Not yet recruiting

Trial end date:
2023-06-01

Target enrollment:

Participant gender:

Summary

The study seeks to investigate safety and efficacy of ixazomib (NINLARO), a proteasome inhibitor, in multiple sclerosis (MS). Participants will receive either ixazomib capsules or placebo capsules for up to 24 months.

Phase:

Phase 1

Details

Lead Sponsor:

Queen Mary University of London

Collaborator:

Takeda Pharmaceuticals International, Inc.

Treatments:

Glycine
Ixazomib